The Common Rule plays a significant role in the governance of observational studies. The Common Rule refers to a set of regulations and ethical principles designed to protect human subjects participating in research studies conducted or supported by federal agencies in the United States. It sets the standards for the ethical conduct of research and ensures the protection of individuals involved in research studies.
Observational studies, which are a type of study design used in RWE research, involve the collection and analysis of data from participants in their real-world settings. These studies aim to assess outcomes and associations between various factors, such as treatments, interventions, or exposure to certain conditions, without any intervention or manipulation by the researcher.
The Common Rule establishes the following key principles and requirements:
Informed Consent: The Common Rule emphasizes the importance of obtaining informed consent from individuals participating in research studies. Researchers must provide participants with clear and understandable information about the study, its purpose, risks, potential benefits, and any other relevant details. Informed consent ensures that participants have the necessary information to make an informed decision about their participation.
Institutional Review Board (IRB) Oversight: The Common Rule requires that all research involving human subjects undergo review by an IRB. The IRB evaluates the study’s ethical implications, safeguards the rights and welfare of participants, and ensures that the research adheres to the Common Rule’s principles. IRBs play a critical role in assessing the risks and benefits of observational studies and determining whether they meet ethical standards.
Privacy and Confidentiality: Observational studies often involve the collection of sensitive data from participants, such as medical records or personal information. The Common Rule mandates that researchers take appropriate measures to protect the privacy and confidentiality of individuals involved in the study. This includes implementing safeguards to prevent unauthorized access, use, or disclosure of participant data.
Balancing Risks and Benefits: The Common Rule requires researchers to conduct a thorough risk-benefit analysis of the observational study. They must assess the potential risks associated with data collection and analysis and weigh them against the potential benefits of the research. This analysis helps ensure that the benefits of the study justify any potential risks to the participants.
By adhering to the Common Rule, researchers can ensure that observational studies in RWE are conducted ethically, with proper safeguards for participant rights, welfare, and privacy. The Common Rule helps maintain the integrity of research and promotes public trust in the scientific community’s ability to generate reliable and valuable real-world evidence.
Share this story...
Real World Evidence (RWE) 101 – Registry vs Registry-Based Study
RWE 101 - Registry vs Registry-Based Study In the context of real-world evidence, a registry is a collection of data on a particular disease, medical condition, or [...]
Real World Evidence (RWE) 101 – Pregnancy Registries
RWE 101 - Pregnancy Registries A pregnancy registry is a type of real-world evidence collection system that collects data from pregnant women who have been exposed to [...]
Real World Evidence (RWE) 101 – Diversity
RWE 101 - Diversity Diversity in the context of real-world research refers to the inclusion of individuals from different backgrounds, including but not limited to race, ethnicity, gender, [...]
Real World Evidence (RWE) 101 – The Patient Voice
RWE 101 - The Patient Voice The patient voice refers to the perspectives, opinions, and experiences of patients and their families or caregivers in the context of [...]
Real World Evidence (RWE) 101 – ISPE GPP
RWE 101 - ISPE GPP The International Society of Pharmacoepidemiology (ISPE) Good Pharmacoepidemiology Practices (GPP) provides guidance for the conduct and reporting of pharmacoepidemiologic studies. The key [...]
Real World Evidence (RWE) 101 – EMA Good Pharmacovigilance Practices (GVPs)
RWE 101 - EMA Good Pharmacovigilance Practices (GVPs) The European Medicines Agency's (EMA) Good Pharmacovigilance Practices (GVPs) provide a framework for the monitoring and reporting of adverse drug [...]







